This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Verapamil and hyperprolactinaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • verapamil has a significant prolactin releasing effect - a study revealed that 8.5% of male patients treated with verapamil had increased prolactin levels with a concomitant reduction in testosterone levels (1) - this prolactin releasing effect is not significant with other calcium antagonists

  • verapamil may lead to hyperprolactinaemia via antagonism of N-type calcium channels and consequent decrease in central dopamine production

Reference:

  • 1) Romeo JH et al. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 1996;45:571-5.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.